Bavarian Nordic A/S buy MBU
Start price
10.10.24
/
50%
€28.22
Target price
10.11.24
-
Performance (%)
-0.82%
End price
11.11.24
€27.99
Summary
This prediction ended on 11.11.24 with a price of €27.99. During the runtime of the prediction for Bavarian Nordic A/S the price only changed by -0.82%. MBU has 50% into this predictionBavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Bavarian Nordic A/S | -2.686% | -2.686% | -4.087% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by MBU for this prediction
In the thread Trading Bavarian Nordic A/S
Die von MBU gewählte maximale Laufzeit wurde überschritten